Dan Skovronsky knows what makes obesity drugs a good one.
As Chief Science Officer YililaiHe has used the company’s Weekly Shooting, Zepbound. He tried to do it again with a more convenient daily medicine and then repeated the feat with a more powerful lens than Zepbough. This does not count the testing of the other nine obesity drugs in clinical trials.
Skovlensky said the contest to create the next great drug is no longer just weight loss, more investors and analysts are starting to say.
take AnjinExperimental pharmaceutical marine agents: People lose 20% In the second phase of the study, their weight and Amgen stock fell by about 5% on the day of November’s release. Why? Investors are worried that competing with Eli Lilly’s Zepbough and Novo Nordisk’s Wegovy isn’t enough, both of which will have a year-round start.
On Thursday, March 28, 2024, an Eli Lilly & Co was arranged in Brooklyn, New York, USA. Zepbound Indention Pen.
Shelby Knowles | Bloomberg | Getty Images
Skovornsky believes that it can improve ease of use and make more effective drugs two paths forward. He envisioned pills like Lilly’s Orforglipron that could cover people around the world. He believes that drugs that can reduce weight (may include vicatrutide from the body) are another area of ​​potential.
But he was most excited to see other health conditions that urinary sterol or intestinal hormones could treat. Lily’s recent zepbound is Approved for treatment of sleep apnea. The company also explores whether it can be cured Addiction, heart disease, inflammation and gastrointestinal conditions.
You can watch a full interview with Skovronsky to see how Lilly works in obesity and where he sees the market move forward.
